Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of lurasidone in pediatric schizophrenia and autism-related irritability
2013-001694-24Phase 3Completed
- Sponsor
- Sunovion
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lurasidone in schizophrenia and Autism Spectrum Disorder (ASD) (2 arms), sponsored by Sunovion. Primary endpoint: Safety assessments. Started Nov 2013; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophreniaAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2013-001694-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001694-24.